Clinical Trial Update: the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of anlotinib and almonertinib as first-line therapy for brain metastases in EGFR mutation-positive non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• Anlotinib (anlotinib)

Snippet

Sponsor: Li-kun Chen | Conditions: Non-small Cell Lung Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN